CARDIAC ARRHYTHMIAS CAUSED BY HYDROXYZINE USE
Abstract
Hydroxyzine, an H1 receptor antagonist, is a drug commonly used to treat anxiety, pruritus, urticaria or used during premedication before surgery. It was introduced to the market as early as the 1950s, but it was not until 2015 that a warning was issued regarding its potential to cause arrhythmias. This action is due to its effect on the transport of potassium ions through ion channels in myocardial cells, leading to a prolongation of the QT segment, which can contribute to torsade de pointes-type arrhythmias.
Numerous clinical cases of cardiac arrhythmias and QT prolongation following hydroxyzine use have been reported in the literature. This is most likely to occur in patients with comorbidities, genetic factors that prolong the QT segment, or those taking other drugs that can cause arrhythmias.
Meta-analyses of safety reports published by manufacturers of drugs containing hydroxyzine and non-clinical studies also provide information on the potential for cardiac torsade de pointes arrhythmias while taking hydroxyzine.
Therefore, it is extremely important to take a thorough patient history before initiating hydroxyzine treatment, to rule out risk factors for cardiac arrhythmias, and to assess the benefits and risks of the drug. This is particularly important in elderly patients and those suffering from multiple chronic diseases.
Extreme caution should also be exercised when administering hydroxyzine to patients in emergency conditions in a hospital emergency department setting or by emergency medical teams, when it may not be possible to establish an accurate history.
Despite the high efficacy of hydroxyzine in both reducing symptoms of anxiety, pruritus and premedication preoperatively, the potential risk of cardiac arrhythmias in certain groups of patients should always be considered and the benefit/risk ratio assessed when including treatment.
References
Summary of product characteristics: Hydroxizinum Hasco 10mg, Hydroxizinum Hasco 25mg.
Drug database: Hydroxyzine. (2025, April 18). Retrieved from http://www.mp.pl
Woroń, J., Drygalski, T., Lonc, T., Wordliczek, J., Gupało, J., Sanak, T., Putowski, M. (2024). Causes of drug complications in emergency medicine, practical aspects only - top 10. Anesthesiology and Emergency Medicine, 18, 147–153.
Editorial. Woroń, J. (2023). Meanders of modern pharmacotherapy. Medical Tribune Poland.
Editorial. Tyminski, R., & Woroń, J. (2020). Adverse drug interactions: Clinical and legal aspects. Medical Tribune Poland, Warsaw.
Woroń, J., Siwek, M., & Wasik, A. (2019). Drug interactions in psychiatry. Asteriamed Gdansk.
Kaski, J. C., & Kjeldsen, K. P. (Eds.). (2019). The ESC handbook on cardiovascular pharmacotherapy. Oxford University Press.
Shear, N. H. (2023). Drug Eruption & Reaction Manual. CRC Press.
Kaito, K., Akihiro, E., Nobuhide, W., Koichi, O., & Kazuaki, T. (2021). Hydroxyzine-induced Torsade de Pointes in a patient with complete atrioventricular block. Internal Medicine, 60(20), 3257–3260.
Pitak, M. (2017, July 13). Ventricular arrhythmias part 2: ECG testing in pediatric practice. Indication, performance, and interpretation. Retrieved April 21, 2025, from http://www.mp.pl
Afzal, M., Khalid, N., Abdullah, M., et al. (2023, July 9). Hydroxyzine-induced Torsade De Pointes: A case report and a literature review. Cureus, 15(7), e41588. https://doi.org/10.7759/cureus.41588
Acosta-Materán, C., Díaz-Oliva, E., Fernández-Rodríguez, D., & Hernández-Afonso, J. (2016). QT interval prolongation and torsade de pointes: Synergistic effect of flecainide and H1 receptor antagonists. Journal of Pharmacology and Pharmacotherapeutics, 7(2), 102–105.
Schlit, A.-F., Delaunois, A., Colomar, A., Claudio, B., Cariolato, L., Boev, R., Valentin, J.-P., Peters, C., Sloan, V. S., Bentz, J. W. G. (2017). Risk of QT prolongation and torsade de pointes associated with exposure to hydroxyzine: Re-evaluation of an established drug. Pharma Res Per, 5(3), e00309. https://doi.org/10.1002/prp2.309
Lee, B., Lee, S., Chu, D., et al. (2011). Effects of the histamine H1 receptor antagonist hydroxyzine on hERG K+ channels and cardiac action potential duration. Acta Pharmacologica Sinica, 32, 1128–1137. https://doi.org/10.1038/aps.2011.66
Sakaguchi, T., Itoh, H., Ding, W. G., Tsuji, K., Nagaoka, I., Oka, Y., Ashihara, T., Ito, M., Yumoto, Y., Zenda, N., Higashi, Y., Takeyama, Y., Matsuura, H., & Horie, M. (2008). Hydroxyzine, a first-generation H1-receptor antagonist, inhibits human ether-a-go-go-related gene (HERG) current and causes syncope in a patient with the HERG mutation. Journal of Pharmacological Sciences, 108(4), 462–471. https://doi.org/10.1254/jphs.08178FP
European Medicines Agency. (2015). New restrictions to minimize the risks of effects on heart rhythm with hydroxyzine-containing medicines. Retrieved April 23, 2025, from https://www.ema.europa.eu
Morales, D. R., Macfarlane, T., MacDonald, T. M., et al. (2021). Impact of EMA regulatory label changes on hydroxyzine initiation, discontinuation, and switching to other medicines in Denmark, Scotland, England, and the Netherlands: An interrupted time series regression analysis. Pharmacoepidemiology and Drug Safety, 30, 482–491. https://doi.org/10.1002/pds.5191
Morrow, R. L., Mintzes, B., & Souverein, P. C. (2022). Hydroxyzine initiation following drug safety advisories on cardiac arrhythmias in the UK and Canada: A longitudinal cohort study. Drug Safety, 45, 623–638. https://doi.org/10.1007/s40264-022-01175-2
Perry, L. T., Bhasale, A., Fabbri, A., Lexchin, J., Puil, L., Joarder, M., et al. (2020). A descriptive analysis of medicines safety advisories issued by national medicines regulators in Australia, Canada, the United Kingdom, and the United States: 2007 to 2016. Pharmacoepidemiology and Drug Safety, 29(9), 1054–1063. https://doi.org/10.1002/pds.5072
Davila, I., Sastre, J., Bartra, J., Del Cuvillo, A., Jáuregui, I., Montoro, J., et al. (2006). Effect of H1 antihistamines upon the cardiovascular system. Journal of Investigational Allergology and Clinical Immunology, 16(Suppl 1), 13–23.
European Medicines Agency. (2015). PRAC recommends new measures to minimize known heart risks of hydroxyzine-containing medicines. Retrieved February 13, 2015, from http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2015/02/WC500182462.pdf
Gintant, G. A., Su, Z., Martin, R. L., & Cox, B. F. (2006). Utility of hERG assays as surrogate markers of delayed cardiac repolarization and QT safety. Toxicologic Pathology, 34, 81–90.
Hancox, J. C., McPate, M. J., El Harchi, A., & Zhang, Y. H. (2008). The hERG potassium channel and hERG screening for drug-induced torsades de pointes. Pharmacology & Therapeutics, 119, 118–132.
Redfern, W., Carlsson, L., Davis, A., Lynch, W. G., MacKenzie, I., Palethorpe, S., et al. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation, and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovascular Research, 58, 32–45.
Sakaguchi, T., Itoh, H., Ding, W. G., Tsuji, K., Nagaoka, I., Oka, Y., et al. (2008). Hydroxyzine, a first-generation H1-receptor antagonist, inhibits human ether-a-go-go-related gene (HERG) current and causes syncope in a patient with the HERG mutation. Journal of Pharmacological Sciences, 108, 462–471.
Vigne, J., Alexandre, J., Fobe, F., Milliez, P., Loilier, M., Fedrizzi, S., et al. (2015). QT prolongation induced by hydroxyzine: A pharmacovigilance case report. European Journal of Clinical Pharmacology, 71, 379–381.
Zeltser, D., Justo, D., Halkin, A., Prokhorov, V., Heller, K., Viskin, S. (2003). Torsade de pointes due to noncardiac drugs: Most patients have easily identifiable risk factors. Medicine, 82, 282–290.
Valentin, J. P., Pollard, C., Lainée, P., & Hammond, T. (2010). Value of non-clinical cardiac repolarization assays in supporting the discovery and development of safer medicines. British Journal of Pharmacology, 159, 25–33
Views:
93
Downloads:
42
Copyright (c) 2025 Kamil Łebek, Patryk Biesaga, Julia Lipiec, Alicja Bury, Konrad Kotte, Weronika Sobota, Przemysław Piskorz, Daria Litworska-Sójka, Bartosz Komsta, Wojciech Pabis
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
